| FAMI 0.2038 71.69% | RITR 0.0999 13.27% | MGN 0.1318 10.20% | NVDA 227.2101 4.49% | LHAI 1.0256 24.95% | NVD 3.6882 -8.93% | GPRO 1.4 13.82% | VIVK 0.9327 18.98% | PPBT 2.2601 36.15% | GPUS 0.2021 -15.55% | PCG 13.129 -6.62% | BITO 10.4 0.24% | TSLL 9.1501 -1.93% | EOSE 3.4924 14.88% | NU 15.315 5.91% | VIOT 1.575 62.49% | BTAI 0.1147 -16.28% | ONDS 7.4223 5.43% | GELS 0.6373 19.79% | NIO 3.88 -4.32% | BIAF 10.5801 60.55% | SOXS 51.67 -1.05% | INTC 90.1001 1.27% | SOXL 106.8 0.84% | NCPL 1.1113 40.32% | NOK 9.8099 -1.21% | SPCX 140.93 -0.91% | AAL 13.14 1.47% | BBD 3.445 3.77% | TQQQ 69.439 0.42% | F 13.81 -0.22% | RIG 6.12 3.38% | SOFI 17.8472 4.68% | PATH 17.815 -1.79% | PLTR 168.2501 -6.49% | SQQQ 39.825 -0.36% | IBIT 43.81 0.11% | HYG 79.19 0.11% | EWZ 38.045 4.03% | DELL 457.6 7.67% | SMCI 36.36 -0.95% | PLUG 2.085 -0.24% | TSLA 352.86 -0.91% | GTLB 50.8078 12.68% | BTG 5.385 3.56% | CANF 2.539 -22.83% | CNH 13.2215 5.77% | HPE 50.16 -1.40% | IREN 37.79 2.63% | AAPL 325.52 0.12%

Pfizer Raises Profit Forecast After Q2 Earnings Beat

Pfizer (NYSE:PFE) posted better-than-expected second-quarter earnings and revenue and raised its full-year profit outlook, sending shares up over 4% intra-day.

The pharmaceutical giant reported earnings per share of $0.78 for the quarter, ahead of the $0.57 consensus. Revenue rose 10% year-over-year to $14.7 billion, also topping estimates of $13.47 billion.

Chairman and CEO Dr. Albert Bourla said the quarter reflected strong execution, commercial progress, and pipeline advancement. The company cited margin improvement, lower tax rates, and favorable currency moves as drivers of the revised forecast.

Pfizer raised its full-year adjusted EPS guidance to a range of $2.90–$3.10, up $0.10 at the midpoint. The company maintained its full-year revenue forecast of $61.0 billion to $64.0 billion.

Published on: August 5, 2025